Clidinium
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Clidinium
- Pharmacist Assessment Report
- Clidinium: Muscarinic antagonist (quaternary anticholinergic) → cauda equina syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Clidinium: Muscarinic antagonist (quaternary anticholinergic) → cauda equina syndrome
One-Sentence Summary
Clidinium is a quaternary anticholinergic (muscarinic antagonist) that is marketed in India in fixed-dose tablets. The TxGNN model predicts it may be relevant for cauda equina syndrome, with a prediction score of 0.9993. There are no clinical trials and no publications on this disease, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | cauda equina syndrome |
| TxGNN Prediction Score | 0.9993 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Clidinium is known as a quaternary anticholinergic that blocks muscarinic receptors, which reduces smooth muscle spasm and secretion in the gut.
Cauda equina syndrome involves nerve root compression that often leads to bladder and bowel dysfunction. In principle, an antimuscarinic could ease detrusor or bowel overactivity symptoms. This would be symptom relief only. It would not treat the underlying compression, which needs urgent decompression.
No trials or publications support this use. The prediction should be treated as a hypothesis only. Other antimuscarinics with established bladder evidence, such as oxybutynin and solifenacin, are more natural candidates for such symptoms.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
The data compiled for this report show 20 valid licences, and this list may be partial. The licence records carry no approved-indication text. All listed products are oral tablets. The first five are shown below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 208220 | StayHappi Clidinium+Chlordiazepoxide+Dicyclomine 2.5mg/5mg/10mg Tablet | Strip of 10 tablets | Not recorded |
| 11104 | Avidip 2.5mg/5mg/10mg Tablet | Strip of 10 tablets | Not recorded |
| 38061 | Coldax 2.5mg/5mg/10mg Tablet | Strip of 10 tablets | Not recorded |
| 39483 | Calm Spas Tablet | Strip of 10 tablets | Not recorded |
| 247490 | Zibra 2.5 mg/5 mg/10 mg Tablet | Strip of 10 tablets | Not recorded |
Safety Considerations
- Disease-level cautions (from relationship data, not label text): Clidinium is recorded as contraindicated or to be used with caution in several conditions. Those relevant here include angle-closure glaucoma, myasthenia gravis, benign prostatic hyperplasia, coronary artery disease, hypertension, gastric ulcer, liver disease, kidney disease, gallbladder disease, porphyria, psychotic and anxiety disorders, and sleep apnoea or lung disease.
- Drug Interactions: 192 interactions are recorded. Most of those listed are moderate. They include other anticholinergics (aclidinium, hyoscyamine, amitriptyline), opioids (fentanyl, codeine, tramadol, hydrocodone, alfentanil, dihydrocodeine, loperamide), sedating antihistamines (acrivastine, phenyltoloxamine), ethanol, amantadine, botulinum toxin type A, acetylcholine, phenylephrine and acebutolol. Minor interactions include acetaminophen and hydrochlorothiazide.
- Specific concern for this prediction: Anticholinergics can cause urinary retention. In a condition that already affects bladder function, this would need careful monitoring.
Please also refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high (0.9993), but no trial or publication studies clidinium in cauda equina syndrome. The mechanistic link is only symptomatic and theoretical, and the evidence level is L5.
To proceed, the following is needed:
- Any clinical or preclinical data on clidinium in neurogenic bladder or bowel dysfunction
- Mechanism of action data for clidinium
- Package insert warnings and contraindications
- A comparison against established antimuscarinic options and a plan to monitor for urinary retention
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.